SCHEMBL3249084

SCHEMBL3249084

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)Cc4ccccn4)cc3c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 8/20 0.39
JAK3 P52333 8/20 0.39
KDM4E B2RXH2 1/20 0.39
RAB9A P51151 1/20 0.39
CLEC4M Q9H2X3 1/20 0.38
GABRA1 P14867 4/20 0.38
GABRB2 P47870 4/20 0.38
GABRB1 P18505 3/20 0.38
GABRA3 P34903 3/20 0.38
CDK5 Q00535 2/20 0.38
CDK5R1 Q15078 2/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRA4 P48169 1/20 0.38
GABRE P78334 1/20 0.38
GABRA6 Q16445 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3249036 0.88 TET2 (0.36) KDM4ERAB9AGABRA1GABRB2
SCHEMBL3249920 0.87 GABRA1 (0.47) KDM4ECLEC4MGABRA1GABRB2GABRB1
SCHEMBL3248784 0.87 PARG (0.34) KDM4ERAB9AGABRA1GABRB2GABRB1
SCHEMBL3252578 0.85 GABRA1 (0.41) KDM4ECLEC4MGABRA1GABRB2GABRB1
SCHEMBL3253410 0.83 MET (0.42) JAK2JAK3KDM4ECLEC4MGABRA1
SCHEMBL3242035 0.82 GABRA1 (0.45) KDM4ECLEC4MGABRA1GABRB2GABRB1
SCHEMBL3244720 0.81 GABRA1 (0.44) KDM4ECLEC4MGABRA1GABRB2GABRB1
SCHEMBL3254539 0.80 MAPT (0.48) KDM4E
SCHEMBL4157925 0.79 PNP (0.37) RAB9AGABRA1GABRB2
SCHEMBL3248963 0.79 TAS2R14 (0.44) KDM4ECLEC4MGABRA1GABRB2GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 JAK2 70/4885JAK3 171/4885KDM4E 1970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.